CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on ...
Mayo Clinic researchers have uncovered how aging "zombie cells" trigger harmful inflammation that accelerates a severe and ...
Everyday Health on MSN
MASH: Is semaglutide right for you?
Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.
The authors provide a useful integrated analytical approach to investigating MASLD focused on diverse multiomic integration methods. The strength of evidence for this new resource is solid, as ...
The FDA has qualified AI-Based Histologic Measurement of MASH, or AIM-MASH AI Assist — the first AI drug development tool — ...
Mayo Clinic researchers have discovered how aging "zombie cells" contribute to inflammation that speeds up a serious form of ...
Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...
Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
1. Lou A, Elnenaei M, Liu E, et al. Evaluation of a novel albumin platelet product (APP) fibrosis index and three ...
Microphysiological systems help address the shortcomings of animal models for mAb development, and CN Bio is taking an active ...
Metabolic dysfunction-associated steatotic liver disease (MASLD), a spectrum of liver conditions ranging from simple steatosis to steatohepatitis (MASH), fibrosis, and cirrhosis, represents a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback